Cargando…

The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond

CXCR4 is a pleiotropic chemokine receptor which acts through its ligand CXCL12 to regulate diverse physiological processes. CXCR4/CXCL12 axis plays a pivotal role in proliferation, invasion, dissemination and drug resistance in multiple myeloma (MM). Apart from its role in homing, CXCR4 also affects...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ullah, Tomalika Rahmat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6658931/ https://www.ncbi.nlm.nih.gov/pubmed/31372333 http://dx.doi.org/10.1016/j.jbo.2019.100253

Ejemplares similares

A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments
por: Hervás-Salcedo, Rosario, et al.
Publicado: (2022)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

CXCR4 or CXCR7 antagonists treat endometriosis by reducing bone marrow cell trafficking
por: Pluchino, Nicola, et al.
Publicado: (2020)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

The Role of the Local Bone Marrow Renin-Angiotensin System in Multiple Myeloma
por: Saka, Bülent, et al.
Publicado: (2019)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

Role and Therapeutic Targeting of SDF-1α/CXCR4 Axis in Multiple Myeloma
por: Ito, Shigeki, et al.
Publicado: (2021)

Coexpression of CCR7 and CXCR4 During B Cell Development Controls CXCR4 Responsiveness and Bone Marrow Homing
por: Mcheik, Saria, et al.
Publicado: (2019)

Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Ho, Matthew, et al.
Publicado: (2022)

Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2020)

Investigation of Gene Expressions of Myeloma Cells in the Bone Marrow of Multiple Myeloma Patients by Transcriptome Analysis
por: Sarıman, Melda, et al.
Publicado: (2019)

Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016)

Defective CXCR4 expression in aged bone marrow cells impairs vascular regeneration
por: Shao, Hongwei, et al.
Publicado: (2011)

Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review
por: Lyall, Matthew, et al.
Publicado: (2022)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
por: Harmer, Danielle, et al.
Publicado: (2019)

Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
por: André, Thibaud, et al.
Publicado: (2013)

Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells
por: Falank, Carolyne, et al.
Publicado: (2016)

MIM REGULATES THE TRAFFICKING OF BONE MARROW CELLS VIA MODULATING SURFACE EXPRESSION OF CXCR4
por: Zhan, Tailan, et al.
Publicado: (2016)

CXCR4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow
por: Beck, Thomas C., et al.
Publicado: (2014)

Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma
por: Lee, Nuri, et al.
Publicado: (2015)

Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment
por: Abdi, Jahangir, et al.
Publicado: (2014)

Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma
por: Mathur, Pankaj, et al.
Publicado: (2017)

Exosomes in the Pathogenesis and Treatment of Multiple Myeloma in the Context of the Bone Marrow Microenvironment
por: Chen, Tianzeng, et al.
Publicado: (2020)

Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment
por: Natoni, Alessandro, et al.
Publicado: (2019)

Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma
por: Dziadowicz, Sebastian A., et al.
Publicado: (2022)

Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma
por: Şeyhanlı, Ahmet, et al.
Publicado: (2022)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Bispecific antibodies in multiple myeloma treatment: A journey in progress
por: Cho, Shih-Feng, et al.
Publicado: (2022)

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
por: Zdzisińska, Barbara, et al.
Publicado: (2008)

PGK1 as Predictor of CXCR4 Expression, Bone Marrow Metastases and Survival in Neuroblastoma
por: Ameis, Helen M., et al.
Publicado: (2013)

Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma
por: Kuang, Chunmei, et al.
Publicado: (2023)

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma
por: Spanoudakis, E, et al.
Publicado: (2016)

Glucocorticoid guides mobilization of bone marrow stem/progenitor cells via FPR and CXCR4 coupling
por: Gao, Wenting, et al.
Publicado: (2021)

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells
por: Braga, Walter Moises Tobias, et al.
Publicado: (2014)

TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells
por: Morgan, Jonathan J., et al.
Publicado: (2019)

Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease
por: Bai, Hua, et al.
Publicado: (2017)

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
por: Markovina, Stephanie, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_k17m3mvpf1te9iajp5ra3joci2